Ruxolitinib Devatis 5 mg
Ruxolitinib Devatis 5 mg is a medicine authorised by Swissmedic under authorisation number 70478. The authorisation holder is Devatis AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 24 August 2026 and the authorisation is limited until 23 August 2031. ATC code L01EJ01 places the medicine in the group Antineoplastic agents.
| Authorisation number | 70478 |
|---|---|
| Name | Ruxolitinib Devatis 5 mg |
| Full name | Ruxolitinib Devatis 5 mg, Tabletten |
| Authorisation holder | Devatis AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01EJ01 |
| First authorisation | 24 August 2026 |
| Authorisation validity | 23 August 2031 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Ruxolitinib Devatis 5 mg, Tabletten | A | 24 August 2026 |
| 2 | Ruxolitinib Devatis 10 mg, Tabletten | A | 24 August 2026 |
| 3 | Ruxolitinib Devatis 15 mg, Tabletten | A | 24 August 2026 |
| 4 | Ruxolitinib Devatis 20 mg, Tabletten | A | 24 August 2026 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 56 | Tablette(n) | L01EJ01 | 07.16.1. | A |
| 2 | 56 | Tablette(n) | L01EJ01 | 07.16.1. | A |
| 3 | 56 | Tablette(n) | L01EJ01 | 07.16.1. | A |
| 4 | 56 | Tablette(n) | L01EJ01 | 07.16.1. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Ruxolitinib Devatis 5 mg authorised in Switzerland?
Yes. Ruxolitinib Devatis 5 mg is authorised by Swissmedic under authorisation number 70478, data as of 01 September 2026. The authorisation is limited until 23 August 2031.
Which dispensing category does Ruxolitinib Devatis 5 mg have?
Ruxolitinib Devatis 5 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Ruxolitinib Devatis 5 mg?
The authorisation holder is Devatis AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.